---
schema_version: "secwatch.filing_event.v1"
accession: "0000785161-23-000019"
form_type: "8-K"
ticker: "EHC"
cik: "0000785161"
company_name: "Encompass Health Corp"
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T04:04:03.028239+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Encompass Health reiterates FY2023 guidance; Q1 rehab discharge growth strong through February

## Summary
- Reaffirms FY2023 net operating revenue guidance of $4.68B-$4.76B and adjusted EBITDA of $860M-$900M.
- Reaffirms adjusted EPS guidance of $2.87-$3.16.
- Inpatient rehabilitation discharge growth remained strong through February; anticipates seasonal March impact from spring break.
- CEO Mark Tarr and CFO Doug Coltharp to participate in Barclays Global Healthcare Conference on March 15.

## SEC filing metadata
- accession: 0000785161-23-000019
- form_type: 8-K
- ticker: EHC
- cik: 0000785161
- company_name: Encompass Health Corp
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/785161/000078516123000019/0000785161-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/785161/000078516123000019/ehc-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000785161-23-000019
- JSON: https://secwatch.observer/filing/0000785161-23-000019.json
- Plain text: https://secwatch.observer/filing/0000785161-23-000019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.